MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA: METHODS FOR DETECTION AND QUANTIFICATION.

Authors

Sara Addakiri, Hanaa Bencharef, Asmaa Harrach, Samiha Jaddaoui, Khadija Ait-Ichou, Bouchra Oukkache

Published in

Experimental oncology. Volume 48. Issue 2. Pages 98-107. Aug 21, 2026. Epub Aug 21, 2026.

Abstract

Recently, the identification of minimal residual disease (MRD), also known as measurable residual disease, has seen significant advances driven by the evolving technological landscape in this field. Initially based on raw morphology, the field has since evolved to incorporate karyotyping, cytogenetics, flow cytometry, and other sensitive methods. This updated review discusses key technical considerations for successful MRD detection. We explore the correlation between the results obtained by flow cytometry and molecular genetic techniques.

PMID:
42634847
Bibliographic data and abstract were imported from PubMed on 24 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.